These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 15714174

  • 21. Two strategies for prevention of cytomegalovirus infections after liver transplantation.
    Simon P, Sasse M, Laudi S, Petroff D, Bartels M, Kaisers UX, Bercker S.
    World J Gastroenterol; 2016 Mar 28; 22(12):3412-7. PubMed ID: 27022223
    [Abstract] [Full Text] [Related]

  • 22. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O.
    Transplantation; 2011 Jan 27; 91(2):251-5. PubMed ID: 21099744
    [Abstract] [Full Text] [Related]

  • 23. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
    Perrottet N, Manuel O, Lamoth F, Venetz JP, Sahli R, Decosterd LA, Buclin T, Pascual M, Meylan P.
    BMC Infect Dis; 2010 Jan 06; 10():2. PubMed ID: 20053269
    [Abstract] [Full Text] [Related]

  • 24. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.
    Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, Syrjala KL, Flowers ME, Stevens-Ayers T, Jerome KR, Leisenring W.
    Ann Intern Med; 2015 Jan 06; 162(1):1-10. PubMed ID: 25560711
    [Abstract] [Full Text] [Related]

  • 25. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy.
    Kalil AC, Freifeld AG, Lyden ER, Stoner JA.
    PLoS One; 2009 Jan 06; 4(5):e5512. PubMed ID: 19436751
    [Abstract] [Full Text] [Related]

  • 26. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
    McKeen JT, Tsapepas DS, Li H, Anamisis A, Martin ST.
    Prog Transplant; 2015 Mar 06; 25(1):39-44. PubMed ID: 25758799
    [Abstract] [Full Text] [Related]

  • 27. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
    van der Beek MT, Berger SP, Vossen AC, van der Blij-de Brouwer CS, Press RR, de Fijter JW, Claas EC, Kroes AC.
    Transplantation; 2010 Feb 15; 89(3):320-6. PubMed ID: 20145523
    [Abstract] [Full Text] [Related]

  • 28. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
    Wiita AP, Roubinian N, Khan Y, Chin-Hong PV, Singer JP, Golden JA, Miller S.
    Transpl Infect Dis; 2012 Jun 15; 14(3):248-58. PubMed ID: 22385394
    [Abstract] [Full Text] [Related]

  • 29. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM, Subramaniam S.
    Transpl Infect Dis; 2004 Mar 15; 6(1):3-9. PubMed ID: 15225220
    [Abstract] [Full Text] [Related]

  • 30. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants.
    Weng FL, Patel AM, Wanchoo R, Brahmbhatt Y, Ribeiro K, Uknis ME, Mulgaonkar S, Mathis AS.
    Transplantation; 2007 Feb 15; 83(3):290-6. PubMed ID: 17297403
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of preemptive anti-CMV therapy with valganciclovir after kidney transplantation.
    Lopau K, Greser A, Wanner C.
    Clin Transplant; 2007 Feb 15; 21(1):80-5. PubMed ID: 17302595
    [Abstract] [Full Text] [Related]

  • 32. [Cytomegalovirus viral load and antigenemia in the monitorization of prophylactic treatment with valganciclovir in renal transplant recipients].
    Bordils A, Molina JM, Córdoba J, Ramos D, Beneyto I, Mascarós V, Sánchez Plumed J.
    Rev Esp Quimioter; 2005 Sep 15; 18(3):226-9. PubMed ID: 16369665
    [Abstract] [Full Text] [Related]

  • 33. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
    Torre-Cisneros J, Caston-Osorio JJ, Martín C, Rivero A, Doblas A, Rojas R, Gómez P, Martínez F, Torres A.
    Enferm Infecc Microbiol Clin; 2010 Jan 15; 28(1):6-12. PubMed ID: 19409666
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.
    Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK.
    Pharmacotherapy; 2004 Oct 15; 24(10):1323-30. PubMed ID: 15628830
    [Abstract] [Full Text] [Related]

  • 35. High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic stem cell transplant cytomegalovirus infection.
    Saleh AJ, Al Mohareb F, Al Rabiah F, Chaudhri N, Al Sharif F, Al Zahrani H, Mohamed SY, Patel M, Rasheed W, Nurgat Z, Bakr M, Ahmed S, Zaidi S, Nasser A, Ibrahim K, Al Abdely H, Aljurf M.
    Hematol Oncol Stem Cell Ther; 2010 Oct 15; 3(3):116-20. PubMed ID: 20890068
    [Abstract] [Full Text] [Related]

  • 36. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
    van der Heiden PL, Kalpoe JS, Barge RM, Willemze R, Kroes AC, Schippers EF.
    Bone Marrow Transplant; 2006 Apr 15; 37(7):693-8. PubMed ID: 16501590
    [Abstract] [Full Text] [Related]

  • 37. Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients.
    Liu AW, Jutivorakool K, Fisher CE, Rakita RM, Reyes JD, Bhattacharya RB, Jerome KR, Limaye AP.
    Transplantation; 2018 Apr 15; 102(4):632-639. PubMed ID: 29215460
    [Abstract] [Full Text] [Related]

  • 38. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review.
    Sun HY, Wagener MM, Singh N.
    Am J Transplant; 2008 Oct 15; 8(10):2111-8. PubMed ID: 18828771
    [Abstract] [Full Text] [Related]

  • 39. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
    Humar A, Lipton J, Welsh S, Moussa G, Messner H, Mazzulli T.
    Bone Marrow Transplant; 2001 Sep 15; 28(5):485-90. PubMed ID: 11593322
    [Abstract] [Full Text] [Related]

  • 40. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection.
    Boutolleau D, Deback C, Bressollette-Bodin C, Varnous S, Dhedin N, Barrou B, Vernant JP, Gandjbakhch I, Imbert-Marcille BM, Agut H.
    Antiviral Res; 2009 Feb 15; 81(2):174-9. PubMed ID: 19063923
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.